£1.9M
Cambridge Enterprise led the seed financing, which includes backing from Parkwalk, New Grounds, and R42 Group.
"Many researchers would like to get molecular binding data more conveniently and more frequently to guide them through a drug development project. HexagonFab aims to address this need with the Bolt. This investment will enable us to bring our game-changing product to the market. We look forward to the months ahead working closely with our lead customers,"
